Skip to main content
Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
13.78
-0.50 (-3.50%)
At close: Feb 27, 2026, 4:00 PM EST
13.77
-0.01 (-0.08%)
After-hours: Feb 27, 2026, 7:53 PM EST

Intellia Therapeutics Revenue

In the year 2025, Intellia Therapeutics had annual revenue of $67.67M with 16.92% growth. Intellia Therapeutics had revenue of $23.02M in the quarter ending December 31, 2025, with 78.79% growth.

Revenue (ttm)
$67.67M
Revenue Growth
+16.92%
P/S Ratio
23.59
Revenue / Employee
$167,918
Employees
403
Market Cap
1.60B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202567.67M9.79M16.92%
Dec 31, 202457.88M21.60M59.55%
Dec 31, 202336.28M-15.85M-30.40%
Dec 31, 202252.12M19.07M57.69%
Dec 31, 202133.05M-24.94M-43.01%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Harmony Biosciences Holdings 868.45M
Ardelyx 407.32M
Immunocore Holdings 400.02M
Nurix Therapeutics 83.98M
Relay Therapeutics 15.36M
Oculis Holding AG 992.00K
Revenue Rankings

NTLA News

More News